P0735 Safety and Efficacy of Ustekinumab in Indian Patients with Moderate to Severe Crohn’s Disease: A Multicentre, Interventional, Phase IV study
Rupa Banerjee, Vineet Ahuja, Gourdas Choudhuri, Ashok Dalal et autres
Abstract Background Ustekinumab (UST), a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12/23, has been approved globally. It has shown to be well tolerated and effective for the treatment of moderate to severe Crohn’s disease (CD). However, data on UST use …
in (code pays fourni par la source)
0 citations
Journal of Crohn s and Colitis